Alexandra Balcom
CIK 1862147 · Chief Financial Officer · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$10.57M
Companies
2
Total Filings
29
Lifetime Open-Market Net
-$29.56M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NUVL | Chief Financial Officer | 85,733 | $123.25 | $10.57M | -$29.56M | 27 | 2026-06-03 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | — | $15.70 | — | $0 | 2 | 2026-06-03 |
Recent Filings · Page 3 of 3
29 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-02 | NUVL | Mixed | — | -$732.1K | EDGAR |
| 2024-09-04 | NUVL | Mixed | — | -$563.8K | EDGAR |
| 2024-08-02 | NUVL | Mixed | — | -$516.6K | EDGAR |
| 2024-07-02 | NUVL | Mixed | — | -$475.8K | EDGAR |
| 2024-01-09 | NUVL | Grant (A) | +33,300 | $0 | EDGAR |
| 2023-12-20 | NUVL | Mixed | — | -$2.24M | EDGAR |
| 2023-08-01 | NUVL | Mixed | — | -$1.20M | EDGAR |
| 2023-01-06 | NUVL | Grant (A) | — | $0 | EDGAR |
| 2022-01-05 | NUVL | Grant (A) | — | $0 | EDGAR |
Showing 21–29 of 29
Prev
Page 3 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.